-
EP2766733
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP2766733
| EP2766733 - BIOMARKERS OF RENAL DISORDERS [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 12.08.2016 Database last updated on 30.10.2024 | Most recent event Tooltip | 12.08.2016 | Application deemed to be withdrawn | published on 14.09.2016 [2016/37] | Applicant(s) | For all designated states Inserm 101 rue de Tolbiac 75013 Paris / FR | [2014/34] | Inventor(s) | 01 /
TERZI, Fabiola INSERM U845 Centre de Recherche "Croissance et Signalisation" Université Paris Descartes Sorbonne Paris Cité, Hôpital Necker-Enfants Malades, 149 rue de Sèvres F-75015 Paris / FR | 02 /
CANAUD, Guillaume INSERM U845 Centre de Recherche "Croissance et Signalisation" Université Paris Descartes Sorbonne Paris Cité, Hôpital Necker-Enfants Malades, 149 rue de Sèvres F-75015 Paris / FR | 03 /
BIENAIME, Franck INSERM U845 Centre de Recherche "Croissance et Signalisation" Université Paris Descartes Sorbonne Paris Cité, Hôpital Necker-Enfants Malades, 149 rue de Sèvres F-75015 Paris / FR | [2014/34] | Representative(s) | Plasseraud IP 104 Rue de Richelieu CS92104 75080 Paris Cedex 02 / FR | [N/P] |
| Former [2014/34] | Cabinet Plasseraud 52, rue de la Victoire 75440 Paris Cedex 09 / FR | Application number, filing date | 12770167.0 | 12.10.2012 | WO2012EP70330 | Priority number, date | EP20110185175 | 14.10.2011 Original published format: EP 11185175 | [2014/34] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | WO2013053919 | Date: | 18.04.2013 | Language: | EN | [2013/16] | Type: | A2 Application without search report | No.: | EP2766733 | Date: | 20.08.2014 | Language: | EN | The application published by WIPO in one of the EPO official languages on 18.04.2013 takes the place of the publication of the European patent application. | [2014/34] | Search report(s) | International search report - published on: | EP | 06.06.2013 | Classification | IPC: | G01N33/68 | [2014/34] | CPC: |
G01N33/6893 (EP,US);
G01N33/573 (US);
A61K31/436 (US);
G01N2333/91205 (US);
G01N2800/347 (EP,US);
G01N2800/52 (US)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2014/34] | Title | German: | BIOMARKER FÜR NIERENERKRANKUNGEN | [2014/34] | English: | BIOMARKERS OF RENAL DISORDERS | [2014/34] | French: | BIOMARQUEURS DE TROUBLES RÉNAUX | [2014/34] | Entry into regional phase | 27.03.2014 | National basic fee paid | 27.03.2014 | Designation fee(s) paid | 27.03.2014 | Examination fee paid | Examination procedure | 27.03.2014 | Amendment by applicant (claims and/or description) | 27.03.2014 | Examination requested [2014/34] | 20.11.2015 | Despatch of a communication from the examining division (Time limit: M04) | 31.03.2016 | Application deemed to be withdrawn, date of legal effect [2016/37] | 28.04.2016 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2016/37] | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 20.11.2015 | Fees paid | Renewal fee | 23.10.2014 | Renewal fee patent year 03 | 26.10.2015 | Renewal fee patent year 04 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [X]WO2010135671 (US HEALTH [US], et al) [X] 9 * paragraph [0019]; claims 18-22 *; | [IY] - VOLLENBRÖKER BEATE ET AL, "mTOR regulates expression of slit diaphragm proteins and cytoskeleton structure in podocytes.", AMERICAN JOURNAL OF PHYSIOLOGY. RENAL PHYSIOLOGY FEB 2009 LNKD- PUBMED:19019920, (200902), vol. 296, no. 2, ISSN 1931-857X, pages F418 - F426, XP008149174 [I] 1-9,13,14 * page F423 - page F425 * * page 421, column 1, paragraphs 1,2; figure 2 * [Y] 1-8 DOI: http://dx.doi.org/10.1152/ajprenal.90319.2008 | [Y] - PU X ET AL, "PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy", LUNG CANCER, ELSEVIER, AMSTERDAM, NL, vol. 71, no. 1, ISSN 0169-5002, (20110101), pages 82 - 88, (20101217), XP027563947 [Y] 1-8 * abstract * | [X] - MORALES ET AL, "Conversion From a Calcineurin Inhibitor-Based Immunosuppressive Regimen to Everolimus in Renal Transplant Recipients: Effect on Renal Function and Proteinuria", TRANSPLANTATION PROCEEDINGS, ELSEVIER INC, ORLANDO, FL; US, (20070417), vol. 39, no. 3, doi:10.1016/J.TRANSPROCEED.2006.12.026, ISSN 0041-1345, pages 591 - 593, XP022033278 [X] 13,14 * abstract * DOI: http://dx.doi.org/10.1016/j.transproceed.2006.12.026 | [A] - BERTOLINI L ET AL, "Subclinical Interstitial Lung Abnormalities in Stable Renal Allograft Recipients in the Era of Modern Immunosuppression", TRANSPLANTATION PROCEEDINGS, (201109), vol. 43, no. 7, pages 2617 - 2623, XP008149252 [A] 1-8 * abstract * DOI: http://dx.doi.org/10.1016/j.transproceed.2011.06.033 | [A] - GÖDEL MARKUS ET AL, "Role of mTOR in podocyte function and diabetic nephropathy in humans and mice.", THE JOURNAL OF CLINICAL INVESTIGATION JUN 2011 LNKD- DOI:10.1172/JCI44774 PUBMED:21606591, (201106), vol. 121, no. 6, ISSN 1558-8238, pages 2197 - 2209, XP008149178 [A] 1-8 * the whole document * DOI: http://dx.doi.org/10.1172/JCI44774 | [A] - FOGO AGNES B, "The targeted podocyte.", THE JOURNAL OF CLINICAL INVESTIGATION JUN 2011 LNKD- DOI:10.1172/JCI57935 PUBMED:21606599, (201106), vol. 121, no. 6, ISSN 1558-8238, pages 2142 - 2145, XP008149177 [A] 1-8 * the whole document * DOI: http://dx.doi.org/10.1172/JCI57935 | by applicant | WO9932619 | WO0136646 | WO0168836 | WO02055693 | US6506559 | US6573099 | - TUSCHL, T. ET AL., GENES DEV., (19991215), vol. 13, no. 24, pages 3191 - 7 | - ELBASHIR, S. M. ET AL., NATURE, (20010524), vol. 411, no. 6836, pages 494 - 8 | - HANNON, GJ., NATURE, (20020711), vol. 418, no. 6894, pages 244 - 51 | - MCMANUS, MT. ET AL., J IMMUNOL, (2002), vol. 169, pages 5754 - 5760 | - BRUMMELKAMP, TR. ET AL., SCIENCE, (20020419), vol. 296, no. 5567, pages 550 - 3 | - HERON, M. ET AL., "Deaths: final data for 2006", NATL VITAL STAT REP, (2009), vol. 57, pages 1 - 134 | - EKNOYAN, G. ET AL., "The burden of kidney disease: improving global outcomes", KIDNEY INT, (2004), vol. 66, pages 1310 - 1314 | - GO, A.S.; CHERTOW, G.M.; FAN, D.; MCCULLOCH, C.E.; HSU, C.Y., "Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization", N ENGL J MED, (2004), vol. 351, pages 1296 - 1305 | - HOSTETTER, T.H., "Progression of renal disease and renal hypertrophy", ANNU REV PHYSIOL, (1995), vol. 57, pages 263 - 278 | - HOSTETTER, T.H., "Hyperfiltration and glomerulosclerosis", SEMIN NEPHROL, (2003), vol. 23, pages 194 - 199 | - KRIZ, W.; LEHIR, M., "Pathways to nephron loss starting from glomerular diseases- insights from animal models", KIDNEY INT, (2005), vol. 67, doi:doi:10.1111/j.1523-1755.2005.67097.x, pages 404 - 419, XP002373456 DOI: http://dx.doi.org/10.1111/j.1523-1755.2005.67097.x | - FRANKE, T.F., "PI3K/Akt: getting it right matters", ONCOGENE, (2008), vol. 27, pages 6473 - 6488 | - CECI, M.; ROSS, J., JR.; CONDORELLI, G., "Molecular determinants of the physiological adaptation to stress in the cardiomyocyte: a focus on AKT", JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, (2004), vol. 37, doi:doi:10.1016/j.yjmcc.2004.06.020, pages 905 - 912, XP004620243 DOI: http://dx.doi.org/10.1016/j.yjmcc.2004.06.020 | - MANNING, B.D.; CANTLEY, L.C., "AKT/PKB signaling: navigating downstream", CELL, (2007), vol. 129, pages 1261 - 1274 | - OUDIT, G.Y. ET AL., "Loss of PTEN attenuates the development of pathological hypertrophy and heart failure in response to biomechanical stress", CARDIOVASC RES, (2008), vol. 78, pages 505 - 514 | - WU, M.; FALASCA, M.; BLOUGH, E.R., "Akt/protein kinase B in skeletal muscle physiology and pathology", J CELL PHYSIOL, vol. 226, pages 29 - 36 | - TEJADA, T. ET AL., "Failure to phosphorylate AKT in podocytes from mice with early diabetic nephropathy promotes cell death", KIDNEY INT, (2008), vol. 73, pages 1385 - 1393 | - STYLIANOU, K. ET AL., "The PI3K/Akt/mTOR pathway is activated in murine lupus nephritis and downregulated by rapamycin", NEPHROL DIAL TRANSPLANT, vol. 26, pages 498 - 508 | - CHUANG, P.Y.; HE, J.C., "Signaling in regulation of podocyte phenotypes", NEPHRON PHYSIOL, (2009), vol. 111, pages 9 - 15 | - SHANKLAND, S.J., "The podocyte's response to injury: role in proteinuria and glomerulosclerosis", KIDNEY INT, (2006), vol. 6, pages 2131 - 2147 | - MUNDEL, P.; REISER, J., "Proteinuria: an enzymatic disease of the podocyte?", KIDNEY INT, vol. 77, pages 571 - 580 | - ZHU, J. ET AL., "Nephrin mediates actin reorganization via phosphoinositide 3-kinase in podocytes", KIDNEY INT, (2008), vol. 73, pages 556 - 566 | - HUBER, T.B. ET AL., "Nephrin and CD2AP associate with phosphoinositide 3-OH kinase and stimulate AKT-dependent signaling", MOL CELL BIOL, (2003), vol. 23, pages 4917 - 4928 | - PILLEBOUT, E. ET AL., "Proliferation and remodeling of the peritubular microcirculation after nephron reduction: association with the progression of renal lesions", AM JPATHOL, (2001), vol. 159, pages 547 - 560 | - TSCHOPP, O. ET AL., "Essential role of protein kinase B gamma (PKB gamma/Akt3) in postnatal brain development but not in glucose homeostasis", DEVELOPMENT, (2005), vol. 132, pages 2943 - 2954 | - YUMURA, W. ET AL., "Age-associated changes in renal glomeruli of mice", EXP GERONTOL, (1989), vol. 24, doi:doi:10.1016/0531-5565(89)90015-6, pages 237 - 249, XP025705018 DOI: http://dx.doi.org/10.1016/0531-5565(89)90015-6 | - CHO, H. ET AL., "Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta", SCIENCE, (2001), vol. 292, doi:doi:10.1126/science.292.5522.1728, pages 1728 - 1731, XP002974608 DOI: http://dx.doi.org/10.1126/science.292.5522.1728 | - GAROFALO, R.S. ET AL., "Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKB beta", J CLIN INVEST, (2003), vol. 112, pages 197 - 208 | - JAFFE, A.B.; HALL, A., "Rho GTPases: biochemistry and biology", ANNU REV CELL DEV BIOL, (2005), vol. 21, pages 247 - 269 | - SHIBATA, S. ET AL., "Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease", NAT MED, (2008), vol. 14, pages 1370 - 1376 | - SANDER, E.E.; TEN KLOOSTER, J.P.; VAN DELFT, S.; VAN DER KAMMEN, R.A.; COLLARD, J.G., "Rac downregulates Rho activity: reciprocal balance between both GTPases determines cellular morphology and migratory behavior", J CELL BIOL, (1999), vol. 147, pages 1009 - 1022 | - GONZALEZ, E.; MCGRAW, T.E., "The Akt kinases: isoform specificity in metabolism and cancer", CELL CYCLE (GEORGETOWN, TEX, (2009), vol. 8, pages 2502 - 2508 | - KREIS, H. ET AL., "Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal", JAM SOC NEPHROL, (2004), vol. 15, pages 809 - 817 | - SARBASSOV, D.D. ET AL., "Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB", MOL CELL, (2006), vol. 22, doi:doi:10.1016/j.molcel.2006.03.029, pages 159 - 168, XP002630237 DOI: http://dx.doi.org/10.1016/j.molcel.2006.03.029 | - LETAVERNIER, E.; PE'RALDI, M.N.; PARIENTE, A.; MORELON, E.; LEGENDRE, C., "Proteinuria following a switch from calcineurin inhibitors to sirolimus", TRANSPLANTATION, (2005), vol. 80, pages 1198 - 1203 | - NIRANJAN, T. ET AL., "The Notch pathway in podocytes plays a role in the development of glomerular disease", NAT MED, (2008), vol. 14, pages 290 - 298 | - WEI, C. ET AL., "Modification of kidney barrier function by the urokinase receptor", NAT MED, (2008), vol. 14, doi:doi:10.1038/nm1696, pages 55 - 63, XP055150053 DOI: http://dx.doi.org/10.1038/nm1696 | - REISER, J. ET AL., "Induction of B7-1 in podocytes is associated with nephrotic syndrome", J CLIN INVEST, (2004), vol. 113, doi:doi:10.1172/JCI20402, pages 1390 - 1397, XP055178804 DOI: http://dx.doi.org/10.1172/JCI20402 | - MA, H. ET AL., "Inhibition of podocyte FAK protects against proteinuria and foot process effacement", JAM SOC NEPHROL, vol. 21, pages 1145 - 1156 | - DAI, C. ET AL., "Wnt/beta-catenin signaling promotes podocyte dysfunction and albuminuria", JAM SOC NEPHROL, (2009), vol. 20, doi:doi:10.1681/ASN.2009010019, pages 1997 - 2008, XP009125300 DOI: http://dx.doi.org/10.1681/ASN.2009010019 | - FAOUR, W.H.; THIBODEAU, J.F.; KENNEDY, C.R., "Mechanical stretch and prostaglandin E2 modulate critical signaling pathways in mouse podocytes", CELL SIGNAL, vol. 22, pages 1222 - 1230, XP027059105 | - CHO, H.; THORVALDSEN, J.L.; CHU, Q.; FENG, F.; BIRNBAUM, M.J., "Aktl/PKBalpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice", J BIOL CHEM, (2001), vol. 276, pages 38349 - 38352 | - FAUL, C.; ASANUMA, K.; YANAGIDA-ASANUMA, E.; KIM, K.; MUNDEL, P., "Actin up: regulation of podocyte structure and function by components of the actin cytoskeleton", TRENDS CELL BIOL, (2007), vol. 17, doi:doi:10.1016/j.tcb.2007.06.006, pages 428 - 437, XP022284343 DOI: http://dx.doi.org/10.1016/j.tcb.2007.06.006 | - REISER, J. ET AL., "Podocyte migration during nephrotic syndrome requires a coordinated interplay between cathepsin L and alpha3 integrin", J BIOL CHEM, (2004), vol. 279, doi:doi:10.1074/jbc.M401973200, pages 34827 - 34832, XP008147703 DOI: http://dx.doi.org/10.1074/jbc.M401973200 | - YANAGIDA-ASANUMA, E. ET AL., "Synaptopodin protects against proteinuria by disrupting Cdc42:IRSp53:Mena signaling complexes in kidney podocytes", AM J PATHOL, (2007), vol. 171, pages 415 - 427 | - ZHOU, G.L. ET AL., "Opposing roles for Aktl and Akt2 in Rac/Pak signaling and cell migration", J BIOL CHEM, (2006), vol. 281, pages 36443 - 36453 | - WELSH, G.I. ET AL., "Insulin signaling to the glomerular podocyte is critical for normal kidney function", CELL METAB, vol. 12, pages 329 - 340 | - JOPE, R.S.; JOHNSON, G.V., "The glamour and gloom of glycogen synthase kinase-3", TRENDS BIOCHEM SCI, (2004), vol. 29, doi:doi:10.1016/j.tibs.2003.12.004, pages 95 - 102, XP004489191 DOI: http://dx.doi.org/10.1016/j.tibs.2003.12.004 | - GOTTLIEB, T.M.; LEAL, J.F.; SEGER, R.; TAYA, Y.; OREN, M., "Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis", ONCOGENE, (2002), vol. 21, pages 1299 - 1303 | - ZHOU, B.P. ET AL., "HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation", NAT CELL BIOL, (2001), vol. 3, pages 973 - 982 | - SHEN, E. ET AL., "Rac is required for cardiomyocyte apoptosis during hyperglycemia", DIABETES, (2009), vol. 58, pages 2386 - 2395 | - HARTLEBEN, B. ET AL., "Autophagy influences glomerular disease susceptibility and maintains podocyte homeostasis in aging mice", J CLIN INVEST, vol. 120, pages 1084 - 1096 | - JUNG, C.H.; RO, S.H.; CAO, J.; OTTO, N.M.; KIM, D.H., "mTOR regulation of autophagy", FEBS LETT, vol. 584, pages 1287 - 1295 | - LETAVERNIER, E.; LEGENDRE, C., "mToR inhibitors-induced proteinuria: mechanisms, significance, and management", TRANSPLANTATION REVIEWS, (2008), vol. 22, doi:doi:10.1016/j.trre.2007.12.001, pages 125 - 130, XP022531928 DOI: http://dx.doi.org/10.1016/j.trre.2007.12.001 | - VOLLENBROKER, B. ET AL., "mTOR regulates expression of slit diaphragm proteins and cytoskeleton structure in podocytes", AM J PHYSIOL RENAL PHYSIOL, (2009), vol. 296, doi:doi:10.1152/ajprenal.90319.2008, pages F418 - 426, XP008149174 DOI: http://dx.doi.org/10.1152/ajprenal.90319.2008 | - LINDSLEY, C.W.; BARNETT, S.F.; LAYTON, M.E.; BILODEAU, M.T., "The PI3K/Akt pathway: recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors", CURR CANCER DRUG TARGETS, (2008), vol. 8, pages 7 - 18 | - TERZI, F. ET AL., "Targeted expression of a dominant-negative EGF-R in the kidney reduces tubulo-interstitial lesions after renal injury", J CLIN INVEST, (2000), vol. 106, pages 225 - 234 | - VIAU, A. ET AL., "Lipocalin 2 is essential for chronic kidney disease progression in mice and humans", J CLIN INVEST, (2010), vol. 120, doi:doi:10.1172/jci42004, pages 4065 - 4076, XP002658742 DOI: http://dx.doi.org/10.1172/jci42004 | - MOLLET, G. ET AL., "Podocin inactivation in mature kidneys causes focal segmental glomerulosclerosis and nephrotic syndrome", JAM SOC NEPHROL, (2009), vol. 20, pages 2181 - 2189 | - LAUTRETTE, A. ET AL., "Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic approach", NAT MED, (2005), vol. 11, pages 867 - 874 | - SHANKLAND, S.J.; PIPPIN, J.W.; REISER, J.; MUNDEL, P., "Podocytes in culture: past, present, and future", KIDNEY INTERNATIONAL, (2007), vol. 72, doi:doi:10.1038/SJ.KI.5002291, pages 26 - 36, XP002583641 DOI: http://dx.doi.org/10.1038/SJ.KI.5002291 | - SARBASSOV, D.D. ET AL., "Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton", CURR BIOL, (2004), vol. 14, doi:doi:10.1016/j.cub.2004.06.054, pages 1296 - 1302, XP025916190 DOI: http://dx.doi.org/10.1016/j.cub.2004.06.054 |